Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
NCT03017690 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22
Last updated 2018-12-21
Summary
An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.
Conditions
- Gastroenteropancreatic Neuroendocrine Tumor
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Ipsen Medical Director · Ipsen
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-04-12
- Primary Completion
- 2018-05-30
- Completion
- 2018-05-30
Countries
- United States
Study Locations
More Related Trials
-
Real-world Study on Adjuvant Octreotide Therapy in pNETs
NCT06080204 ·Status: COMPLETED ·Phase: NA
-
A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
NCT02288377 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
NCT00353496 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
NCT02955069 ·Status: COMPLETED ·Phase: PHASE2
-
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
NCT06016855 ·Status: RECRUITING ·Phase: PHASE4
-
Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen
NCT00417209 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
NCT00216372 ·Status: COMPLETED ·Phase: PHASE3
-
Different Patterns of Target Delineation in SBRT for Locally Advanced Pancreatic Cancer
NCT04699539 ·Status: COMPLETED ·Phase: NA
-
Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)
NCT00390182 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
NCT03257033 ·Status: RECRUITING ·Phase: PHASE3
-
Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs
NCT02294006 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas
NCT00001431 ·Status: COMPLETED ·Phase: PHASE1
-
The MetNET-2 Trial
NCT02823691 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer
NCT05861336 ·Status: WITHDRAWN ·Phase: PHASE2
-
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
NCT03290079 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable
NCT01531712 ·Status: TERMINATED ·Phase: PHASE2
-
Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II
NCT02230176 ·Status: COMPLETED ·Phase: PHASE2
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
NCT05746208 ·Status: RECRUITING ·Phase: PHASE2
-
Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors
NCT02489604 ·Status: TERMINATED ·Phase: PHASE2
-
PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours
NCT05053854 ·Status: RECRUITING ·Phase: PHASE1
-
Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
NCT01304160 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
NCT05841420 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
NCT02551991 ·Status: COMPLETED ·Phase: PHASE2
-
Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
NCT01032057 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
NCT05884255 ·Status: RECRUITING ·Phase: PHASE3